Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics Inc
(NQ:
PTGX
)
41.60
-0.08 (-0.19%)
Streaming Delayed Price
Updated: 3:42 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protagonist Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
December 13, 2023
Via
ACCESSWIRE
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
December 12, 2023
Via
ACCESSWIRE
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
November 27, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
November 16, 2023
Via
ACCESSWIRE
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
November 16, 2023
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.
Via
The Motley Fool
The Latest Analyst Ratings for Protagonist Therapeutics
November 03, 2023
Via
Benzinga
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023
Via
ACCESSWIRE
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
October 09, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
November 09, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
November 02, 2023
Via
ACCESSWIRE
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
November 01, 2023
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
November 01, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
October 30, 2023
Via
ACCESSWIRE
What 6 Analyst Ratings Have To Say About Protagonist Therapeutics
September 25, 2023
Via
Benzinga
Protagonist Receives $34 Million from Warrant Exercises
August 09, 2023
Via
ACCESSWIRE
Expert Ratings for Protagonist Therapeutics
July 06, 2023
Via
Benzinga
Protagonist Therapeutics Reports Granting of Inducement Award
October 03, 2023
Via
ACCESSWIRE
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
September 22, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...
Via
FinancialNewsMedia
Protagonist Therapeutics to Present at Upcoming Investor Conferences
September 05, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
August 16, 2023
Via
ACCESSWIRE
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 03, 2023
Via
ACCESSWIRE
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
July 27, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Protagonist Therapeutics Reports Granting of Inducement Award
July 18, 2023
Via
ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
July 13, 2023
We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning.
Via
InvestorPlace
Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive
July 06, 2023
JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35,
Via
Benzinga
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
July 06, 2023
Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at...
Via
Benzinga
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
July 05, 2023
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 04, 2023
Via
Benzinga
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
July 04, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
July 03, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.